Company / R&D per Share
Bristol Myers Squibb R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.79
FY2025
5-year range
$3.59 / $5.20
FY2021-FY2025
Trend
-7.9%
vs FY2024
Sector context
#38 of 208
Health Care
What the data says
Bristol Myers Squibb's r&d per share of $4.79 is higher than 82% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $2.71 in FY2016 to $6.14 in FY2020.
Based on SEC 10-K filings.
4.79 in FY2025 with a 5-year CAGR of -4.8%. Top quartile in the Health Care sector.
Improved from $4.54 to $4.79 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +2.5%
- 5-Year CAGR
- -4.8%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 208This company $4.79 Sector average $28.82
▼
-83.4% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 7.9% year-over-year.
- Ranks #38 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.79 | -7.9% |
| FY2024 | $5.20 | +14.5% |
| FY2023 | $4.54 | +2.1% |
| FY2022 | $4.45 | +23.9% |
| FY2021 | $3.59 | -41.5% |
| FY2020 | $6.14 | +56.8% |
| FY2019 | $3.92 | +31.2% |
| FY2018 | $2.98 | -22.6% |
| FY2017 | $3.85 | +41.9% |
| FY2016 | $2.71 | +20.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026